Thanks for Nodus-ing: Basilea hands off preclinical oncology program for $248M in ongoing anti-infectives pivot

08 Sep 2022
endpts.com
Looks like Basilea Pharmaceutica is getting closer to its final days as an oncology company. The Switzerland-based Roche offshoot said Thursday that it had sold the company’s preclinical PARG checkpoint inhibitor program to UK-based Nodus Oncology. PARG, or poly(ADP-ribose) glycohydrolase, is an enzyme used to repair DNA damage and had been investigated as a potential oncology target. Nodus will be partnering with German research institute Lead Discovery Center GmbH to continue development of the program. Basilea, as part of the sale, is slated to receive upfront and near-term research milestone payments just over $1 million, with eligibility to receive further payments in the $247 million range after reaching development, regulatory and sales milestones. On top of that, Basilea will receive close to 5% of net sales. Basilea $BSLN decided to revamp its R&D work earlier this year, moving away from one of the hottest fields in drug R&D to focus on anti-infectives. As CEO David Veitch said at the time in February: Four months later, Basilea then offloaded an FGFR inhibitor back to Merck, which should be finalized by year’s end. The company added this week that it does not expect any more oncology expenses starting in 2023. Instead of oncology, the company is now focused on antifungals and antibiotics, with one product approved in each disease area — antifungal Cresemba and antibiotic Zevtera. Cresemba is approved in the US, and Zevtera has not been FDA-approved yet. Basilea was unavailable for an interview before publication. CFO Adesh Kaul said in a statement that the company was happy to have found a partner in the DNA damage response space, adding, “We also continue our ongoing partnering discussions for BAL0891 and our second pre-clinical program, for which we aim to complete transactions before the end of 2022.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.